OncoMatch

OncoMatch/Clinical Trials/NCT03582124

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Is NCT03582124 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Panitumumab-IRDye800 for lung carcinoma.

Phase 1/2RecruitingStanford UniversityNCT03582124Data as of Jun 2026

Treatment: Panitumumab-IRDye800This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Panitumumab-IRDye800

Cancer type

Non-Small Cell Lung Carcinoma

Tumor Agnostic

Disease stage

Required: Stage IV, IVA, IVB (AJCC v8)

Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8

Performance status

KARNOFSKY/ECOG/ZUBROD 0–2

Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2

Demographics

Ages ≥ 19

Prior therapy

Cannot have received: investigational drug

Lab requirements

Blood counts

hemoglobin ≥ 9 gm/dl; white blood cell count > 3000/mm^3; platelet count ≥ 100,000/mm^3

Kidney function

serum creatinine ≤ 1.5 times upper reference range

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Stanford University, School of Medicine · Palo Alto, California

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT03582124 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior investigational drug disqualifies patients from enrollment.

What disease stage is eligible?

Stage IV or IVA or IVB is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify